(Q34452996)

2 August 2017

1 reference

title

Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence (English)

1 reference

2 August 2017

0 references

Sproule BA

1

1 reference

2 August 2017

Naranjo CA

series ordinal

2

1 reference

2 August 2017

Brenmer KE

series ordinal

3

1 reference

2 August 2017

Hassan PC

series ordinal

4

1 reference

2 August 2017

1 December 1997

1 reference

Clinical Pharmacokinetics

2 August 2017

1 reference

2 August 2017

33

1 reference

2 August 2017

454-471

1 reference

2 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-199733060-00004

2 August 2017

0 references

cites work

Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.

1 reference

12 December 2020

Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine

1 reference

12 December 2020

Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine

1 reference

12 December 2020

Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.

1 reference

12 December 2020

Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine

1 reference

12 December 2020

Fluvoxamine is a potent inhibitor of cytochrome P4501A2

1 reference

12 December 2020

Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers

1 reference

12 December 2020

Pharmacogenetic phenotyping and genotyping. Present status and future potential.

1 reference

12 December 2020

Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms

1 reference

12 December 2020

Fluvoxamine-tricyclic antidepressant interaction

1 reference

12 December 2020

Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study

1 reference

12 December 2020

Fluoxetine and norfluoxetine are potent inhibitors of P450IID6--the source of the sparteine/debrisoquine oxidation polymorphism

1 reference

12 December 2020

Psychotic depression: advances in conceptualization and treatment

1 reference

12 December 2020

The effect of sertraline on the pharmacokinetics of desipramine and imipramine

1 reference

12 December 2020

Polymorphic O-demethylation of codeine

1 reference

12 December 2020

P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.

1 reference

12 December 2020

The emerging role of cytochrome P450 3A in psychopharmacology

1 reference

12 December 2020

Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).

1 reference

12 December 2020

Increased carbamazepine plasma concentrations after fluoxetine coadministration

1 reference

12 December 2020

Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism

1 reference

12 December 2020

Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients

1 reference

12 December 2020

Fluvoxamine. A review of global drug-drug interaction data

1 reference

12 December 2020

The psychomotor effects of paroxetine alone and in combination with haloperidol, amylobarbitone, oxazepam, or alcohol

1 reference

12 December 2020

Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms

1 reference

12 December 2020

Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation

1 reference

12 December 2020

The effects on performance of two antidepressants, alone and in combination with diazepam

1 reference

12 December 2020

Interactions between sertraline and tricyclic antidepressants

1 reference

12 December 2020

Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine

1 reference

12 December 2020

Citalopram: interaction studies with levomepromazine, imipramine, and lithium

1 reference

12 December 2020

Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors

1 reference

12 December 2020

Newer antidepressants and the cytochrome P450 system

1 reference

12 December 2020

The clinician and drug interactions--an update

1 reference

12 December 2020

Inhibition by fluoxetine of cytochrome P450 2D6 activity.

1 reference

12 December 2020

Antidepressant Usage in Schizophrenia

1 reference

12 December 2020

Pharmacokinetics of antidepressants: why and how they are relevant to treatment

1 reference

12 December 2020

Pharmacogenetic determination of the effects of codeine and prediction of drug interactions

1 reference

12 December 2020

Clinical pharmacokinetics of fluoxetine

1 reference

12 December 2020

Interaction of fluoxetine with tricyclic antidepressants

1 reference

12 December 2020

Elevation of plasma concentrations of haloperidol after the addition of fluoxetine

1 reference

12 December 2020

No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin

1 reference

12 December 2020

Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder

1 reference

12 December 2020

Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Interactions and therapeutic uses

1 reference

12 December 2020

The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol.

1 reference

12 December 2020

Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness

1 reference

12 December 2020

Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings

1 reference

12 December 2020

Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update

1 reference

12 December 2020

Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine

1 reference

12 December 2020

Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner.

1 reference

12 December 2020

Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine.

1 reference

12 December 2020

Fluoxetine, a selective serotonin uptake inhibitor

1 reference

12 December 2020

Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction

1 reference

12 December 2020

Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1'-hydroxy midazolam formation in vitro.

1 reference

12 December 2020

Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans.

1 reference

12 December 2020

Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo

1 reference

12 December 2020

Serious adverse effects of combining fluoxetine and tricyclic antidepressants

1 reference

12 December 2020

Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects

1 reference

12 December 2020

Metabolic polymorphisms

1 reference

12 December 2020

Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness

1 reference

12 December 2020

Influence of fluoxetine on plasma levels of desipramine

1 reference

12 December 2020

The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes

1 reference

12 December 2020

Managing selective serotonin reuptake inhibitor-drug interactions in clinical practice

1 reference

12 December 2020

Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers.

1 reference

12 December 2020

Pharmacogenetics and drug metabolism of newer antidepressant agents.

1 reference

12 December 2020

Carbamazepine coadministration with fluoxetine or fluvoxamine

1 reference

12 December 2020

A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine

1 reference

12 December 2020

The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes

1 reference

12 December 2020

Interaction of fluoxetine with carbamazepine.

1 reference

12 December 2020

A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine.

1 reference

12 December 2020

Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test

1 reference

12 December 2020

Treatment resistance in unipolar depression and other disorders. Diagnostic concerns and treatment possibilities

1 reference

12 December 2020

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

1 reference

12 December 2020

Coadministration of fluvoxamine increases serum concentrations of haloperidol

1 reference

12 December 2020

Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate

1 reference

12 December 2020

Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers

1 reference

12 December 2020

Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine.

1 reference

12 December 2020

Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness

1 reference

12 December 2020

Fluoxetine induces elevation of desipramine level and exacerbation of geriatric nonpsychotic depression

1 reference

12 December 2020

Interaction between carbamazepine and fluvoxamine

1 reference

12 December 2020

Clinical pharmacokinetics of selective serotonin reuptake inhibitors

1 reference

12 December 2020

An interaction of sertraline and desipramine

1 reference

12 December 2020

Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.

1 reference

12 December 2020

Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients

1 reference

12 December 2020

Venlafaxine oxidation in vitro is catalysed by CYP2D6.

1 reference

12 December 2020

Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine

1 reference

12 December 2020

Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants

1 reference

12 December 2020

Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype

1 reference

12 December 2020

Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype

1 reference

12 December 2020

Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone

1 reference

12 December 2020

Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers.

1 reference

12 December 2020

Overview of the pharmacokinetics of fluvoxamine

1 reference

12 December 2020

Increased plasma concentration of imipramine following augmentation with fluvoxamine

1 reference

12 December 2020

Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine

1 reference

12 December 2020

The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.

1 reference

12 December 2020

The prevalence of psychiatric disorders in patients with alcohol and other drug problems

1 reference

12 December 2020

Fluoxetine impairs clearance of alprazolam but not of clonazepam

1 reference

12 December 2020

Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors

1 reference

12 December 2020

10.2165/00003088-199733060-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference